The grant, plainly. On May 30, 2023, ImmPACT-Bio was issued US11660315B2, covering a universal platform for preparing inhibitory CARs. The CPC tags — A61K 35/12/17 (cell therapy), C07K 14/7051, C12N 15/1055/1093 — describe a construct designed to restrain T-cell activity against healthy tissue, addressing the on-target/off-tumor safety problem.
Why a financing desk reads next-gen IP: first-generation CARs validated the field but left safety and solid-tumor problems unsolved. Platforms that address those — inhibitory CARs aimed at sparing healthy tissue — are the next design wave, and the IP defining them is the asset that funds the next round of pre-revenue burn.
The cautionary read: a next-generation platform raises the ceiling but extends the timeline. More novel mechanisms mean more preclinical and clinical work, more financings, and more dilution before value inflection. The runway math is unchanged; the IP defines the ambition the runway is funding.
What the grant does not show: the company's cash, burn, or dilution path. Those are in the filings. The grant establishes the next-gen platform asset and its claimed scope.
The takeaway: treat next-generation cell-therapy platform grants as high-ceiling intangibles that signal a long, dilutive burn — then run the runway math from the filings. ImmPACT-Bio's May 2023 iCAR grant is a dated example of that next-design-wave IP.